Purpura Treatment Market Research Report- Global Forecast To 2027

Purpura Treatment Market Information, by type (nonthrombocytopenic, thrombocytopenic) by drugs (corticosteroids, intravenous immunoglobulin (ivig), romiplostim (nplate), eltrombopag (promacta)) - Forecast to 2027

ID: MRFR/Pharma/1210-HCR | February 2021 | Region: Global | 80 Pages         

1 Report Prologue

2 Market Introduction

2.1 Introduction

2.2 Scope of Study

2.3 Research Objective

2.4 Assumptions & Limitations

2.4.1 Assumptions

2.4.2 Limitations

3 Research Methodology

3.1 Research Process

3.2 Primary Research

3.3 Secondary Research

4 Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Challenges

4.4 Opportunities

5 Market Factor Analysis

5.1 Porterโ€™s Five Forces Model

5.1.1 Bargaining power of suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Supply Chain Analysis

6 Global Purpura Treatment Market, By Type

6.1 Non-thrombocytopenic Purpura

6.2 Thrombocytopenic Purpura

6.3 Allergic Purpura

7 Global Purpura Treatment Market, By Cases

7.1 Acute

7.2 Chronic

8. Global Purpura Treatment Market, By Treatment

8.1 Corticosteroids

8.2 Intravenous Iimmunoglobulin

8.3 Other Drug Therapies

8.3.1 Romiplostim (Nplate)

8.3.2 Eltrombopag (Promacta)

9 Global Purpura Treatment Market, By Regions

9.1 Americas

9.1.1 North America

9.1.1.1 U.S.

9.1.1.2 Canada

9.1.2 South America

9.2 Europe

9.2.1 Western Europe

9.2.1.1 Germany

9.2.1.2 France

9.2.1.3 UK

9.2.1.4 Italy

9.2.1.5 Spain

9.2.1.6 Rest of Western Europe

9.2.2 Eastern Europe

9.3 Asia Pacific

9.3.1 Japan

9.3.2 China

9.3.3 India

9.3.4 Australia

9.3.5 Republic of Korea

9.3.6 Rest of Asia-Pacific

9.4 Middle East & Africa

9.4.1 UAE

9.4.2 Saudi Arabia

9.4.3 Qatar

9.4.4 Rest of Middle East & Africa

10 Competitive Landscape

10.1 Company Share Analysis

10.2 Key Development Landscape

10.2.1 Mergers & Acquisitions

10.2.2 Partnerships & Agreements

10.2.3 New Product Launch

10.2.4 Others

11 Company Profile

11.1 Amgen Inc

11.1.1 Company Overview

11.1.2 Product/Business Overview

11.1.3 Financial Overview

11.1.4 Key Developments

11.2 Bristol-Myers Squibb Company

11.2.1 Company Overview

11.2.2 Product overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.3 F. Hoffman-La Roche

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.4 GlaxoSmithKline Plc.

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Developments

11.5 Grifols Biologicals Inc

11.5.1 Company Overview

11.5.2 Product overview

11.5.3 Financial Overview

11.5.4 Key Developments

11.6 Hovione

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Novartis AG

11.7.1 Company Overview

11.7.2 Product Overview

11.7.3 Financial Overview

11.7.4 Key Developments

11.8 Pfizer Inc.

11.8.1 Company Overview

11.8.2 Product Overview

11.8.3 Financial Overview

11.8.4 Key Developments

11.9 Sanofi

11.9.1 Company Overview

11.9.2 Product Overview

11.9.3 Financial Overview

11.9.4 Key Developments

12 Bibliography

Purpura Treatment Market Overview


The purpura treatment market is expecting a boost based on the recent market predictions for the ongoing forecast period. The global market is expecting to witness the birth of lucrative market opportunities which the global market is expecting to reach by growth by showing a substantial CAGR growth.


Purpura, as a prominent inclusion of the global market, is also referred to as the visibility of blood spots or bleeding of the skin. It appears to be a purple spot that can be seen most easily on the skin. Spots on various body organs and mucosal membranes may also be located, and these are inclusive of the membranes inside the mouth. In terms of a fast-growing market, the purpura treatment market has been considered and is also projected to be growing at an enormous rate. There is enormous demand followed by a seamless flow of the demand and supply chain mechanism that exists in various regions worldwide for purpura treatment.


Various medications, such as intravenous immunoglobulin (IVIG), alongside others like romiplostim (Plate), eltrombopag (Promacta), and many others, are included with the purpura treatment options. These medical drugs cause bone marrow to supply more platelets, and hence, it results in reducing the risk of injuries and bleeding. Purpura further occurs when the vessels of blood and the bloodbath under the various layers of the human skin, lead to spots. Causes for purpura disease include blood clotting disorders, weak vessels, and others like blood vessel inflammation, telangiectasia, or Danlos-Ehlers syndrome.


COVID 19 Analysis


The outbreak of the novel coronavirus pandemic has been a major issue for the functioning of the market as there has been a major demand for medical facilities that help treat the patients that have tested positive for the virus. The global governments are taking major steps to curb the spread of the virus that include introducing strict regulations followed by the need to implement strategies like temporary and permanent lockdowns followed by the restrictions like social distancing are hampering the projected growth for the global growth of the purpura treatment market especially during the ongoing forecast period. Also, the virtual meetings followed by the availability of doctors to meet the attendance requirements of the patients that have tested positive for the virus is the need of the hour.


The arrival of the pandemic has introduced a challenging time for the global markets and the seekers of the purpura treatment market as the cases are rising. However, the global governments are focusing on the development of vaccines followed by the investments in the research and development activities is likely to help the market opt for major developments and expansion during the ongoing forecast period.


Purpura Treatment Market Dynamics


Drivers


As per the market, statistics are to be believed, about 5 out of 100,000 children and 2 out of 100,000 adults are likely to be suffering from the disease of purpura. This is a prominent factor that is giving rise to a huge demand for the purpura treatment market during the ongoing forecast period.


Restraints


However, the growth of the purpura treatment market is likely to be hampered because of the non-availability of medical equipment followed by proper medication for the people who are suffering from the disease. Also, there has been a lack of funding from the correct sources which is another barrier standing in the growth path of the market during the ongoing forecast period.


Technology has a substantial role to play in the development of the purpura treatment market followed by the speedy steps being taken in the field of hematology. Also, prominent steps for the promotion of purpura treatment have therefore been taken. The drivers of the purpura market are inclusive of the rising per capita healthcare expenditure, followed by other market factors like the genetically affected patients with purpura, further various drugs preventing the development of platelets, or the interfering with normal coagulation that need to be worked upon.


Purpura Treatment Market Segment Overview


The purpura treatment market is segmented based on the segments like types, treatment, end-users, and distribution channel owing to the rising need of the global target audience especially during the ongoing forecast period of 2021-2027. The growth amongst the global market segments helps the market investors analyze niche pockets of growth and strategies to approach the market and also, determine your core application areas and the difference in your target markets.


Based on the Types


The purpura treatment market is segmented based on the type and includes senile purpura, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura (TTP), understand Henoch-schönlein purpura, and others.  


Based on the treatment


The market is segmented based on the treatment into medication, surgery, others. The medication sub-segment is further divided into corticosteroid, intravenous immunoglobulin, platelet-stimulating agents, others. The surgery sub-segment includes splenectomy and others. 


Based on the market end-users


The purpura treatment market is segmented into end-users like hospitals, specialty clinics, home care, and many others.


Based on the distribution channel


The global market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others.


Purpura Treatment Market Regional Analysis


The purpura treatment market has been segmented based on the regions as well. The Americas, especially North America, are potentially projected to dominate this market because of its high healthcare costs in the region. In the North American region, the cure is driven by increased awareness of health, followed by the prominence of other factors like the increased chronic diseases and lifestyle. The market is witnessing technological developments in health applications and the availability of adequate insurance cover. In the United States, it affects approximately four to eight per 100.000 children that fall under 15 years of age.


With an increasing awareness of clinical outcomes, followed by the emergence of other market factors like the large population base, and an increased geriatric population. Also, there has been an increase in the diabetic population and technological advancements in medical devices and equipment, the Asian Pacific region is the fastest-growing market with high potential for the purpura treatment market.


Purpura Treatment Market Competitive Landscape


The global growth can be attributed to the functions of the leading vendors operating in the purpura treatment market that are mentioned as follows:



  • Novartis AG

  • Amgen Inc.

  • Bristol-Myers Squibb Company

  • GlaxoSmithKline Plc.

  • Sanofi Winthrop Industrie S.A.


Recent Developments


The Rituxan approach had the patent expired in Oct 2017 Roche Blockbuster for the oncology drugs. The expiry of this drug will lead to the production of Rituximab generics at low prices. In October 2017 the prominent market player - Pfizer is looking for an assessment of Roche rituximab patents. The prominent player - Pfizer had submitted two inter partes reviews petitions on the two Genentech and Rituxan patents.


The rising investments in the field of medicine followed by the development of medicine, equipment, and the correct treatment for the people who are suffering from purpura are helping in the development followed by meeting the anticipated growth rate of the ongoing forecast period.


Another prominent region Europe is accounting for the second-largest market share due to the increased prevalence of bleeding disorders and purpura followed by the emergence of other market factors like the continuous adoption of new technology for the treatment. Also, the Asian Pacific region is expected to account for the largest market share over the coming years especially during the ongoing forecast period for the purpura treatment market due to the presence of the generic manufacturer.


Report Overview


The purpura treatment report has been prepared to give an in-depth analysis of the purpura treatment market to the investors and business market chiefs. Also, the report helps to lay prime focusing on market opportunities and challenges, alongside the trends that are driving the market. The global market report helps and identifies the leading vendors operating in the market while outlining opportunities available for them. This intelligence report that has been prepared is the outcome of an intense study followed by the rigorous assessment of various dynamics shaping the growth path of the global market. The global market plays an important role to nurture a close-knit team of analysts, strategists, business chiefs, and industry experts who offer clients tools, followed by the methodologies, and frameworks to make smarter decisions. The main objective, insights, and actionable analytics provide the global market executives to advance their mission-critical priorities with confidence.



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2020-2027: Substantial CAGR
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   type and drugs
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Bristol-Myers Squibb Company, Pfizer Inc., GlaxoSmithKline Plc., Novartis AG, Hovione, Sanofi Winthrop Industrie S.A., Hoffman-L Roche, Amgen Inc and Grifols Biologicals Inc,
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions
  Key Market Drivers   Technological advancement, macro economical and governing factors


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

High prevalence and rising per-capita healthcare expenditure are major tailwinds pushing the growth of the global purpura treatment market.

Stringent government regulations and the lack of awareness about the conditions are major growth impeders for the global purpura treatment market.

North America holds the largest share in the global purpura treatment market, followed by Europe and the Asia Pacific, respectively.

Bristol-Myers Squibb Company (U.S.), GlaxoSmithKline Plc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), Sanofi Winthrop Industrie (U.S.), Hovione (Portugal), F. Hoffman-La Roche AG (Switzerland), Grifols Biologicals Inc. (U.S.), and Amgen Inc. (U.S.), are some of the top players operating in the global purpura treatment market.

Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global Purpura treatment market adopt to gain a larger competitive advantage.